New developments in the management of relapsed/refractory multiple myeloma – The role of ixazomib

Paul G. Richardson, Shaji K Kumar, Jacob P. Laubach, Claudia Paba-Prada, Neeraj Gupta, Deborah Berg, Helgi van de Velde, Philippe Moreau

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlled TOURMALINE-MM1 study, which demonstrated a 35% improvement in progression-free survival with the all-oral combination of ixazomib plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone alone (median: 20.6 vs 14.7 months; hazard ratio: 0.74, p=0.012; median follow-up 14.7 months). The addition of ixazomib to the lenalidomide–dexamethasone regimen was associated with limited additional toxicity and had no adverse impact on patient-reported quality of life. Common grade ≥3 adverse events with ixazomib include gastrointestinal adverse events, rash, and thrombocytopenia. Here, we review the efficacy, safety, pharmacokinetics, and patient-reported quality of life data seen with ixazomib, and discuss the role of this oral agent in the treatment of patients with relapsed/ refractory multiple myeloma, including in patients with high-risk cytogenetic abnormalities and those with multiple prior therapies.

Original languageEnglish (US)
Pages (from-to)107-121
Number of pages15
JournalJournal of Blood Medicine
Volume8
DOIs
StatePublished - Aug 22 2017

Fingerprint

Multiple Myeloma
Quality of Life
Proteasome Inhibitors
Therapeutics
Patient Safety
Exanthema
Chromosome Aberrations
Thrombocytopenia
Dexamethasone
Disease-Free Survival
Pharmacokinetics
Placebos
ixazomib

Keywords

  • Clinical
  • Efficacy
  • Ixazomib
  • Multiple myeloma
  • Pharmacokinetics
  • Proteasome inhibitor
  • Tolerability

ASJC Scopus subject areas

  • Hematology

Cite this

New developments in the management of relapsed/refractory multiple myeloma – The role of ixazomib. / Richardson, Paul G.; Kumar, Shaji K; Laubach, Jacob P.; Paba-Prada, Claudia; Gupta, Neeraj; Berg, Deborah; van de Velde, Helgi; Moreau, Philippe.

In: Journal of Blood Medicine, Vol. 8, 22.08.2017, p. 107-121.

Research output: Contribution to journalReview article

Richardson, PG, Kumar, SK, Laubach, JP, Paba-Prada, C, Gupta, N, Berg, D, van de Velde, H & Moreau, P 2017, 'New developments in the management of relapsed/refractory multiple myeloma – The role of ixazomib', Journal of Blood Medicine, vol. 8, pp. 107-121. https://doi.org/10.2147/JBM.S102328
Richardson, Paul G. ; Kumar, Shaji K ; Laubach, Jacob P. ; Paba-Prada, Claudia ; Gupta, Neeraj ; Berg, Deborah ; van de Velde, Helgi ; Moreau, Philippe. / New developments in the management of relapsed/refractory multiple myeloma – The role of ixazomib. In: Journal of Blood Medicine. 2017 ; Vol. 8. pp. 107-121.
@article{9ae2ee1557864551ab2d982bb84544cb,
title = "New developments in the management of relapsed/refractory multiple myeloma – The role of ixazomib",
abstract = "Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlled TOURMALINE-MM1 study, which demonstrated a 35{\%} improvement in progression-free survival with the all-oral combination of ixazomib plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone alone (median: 20.6 vs 14.7 months; hazard ratio: 0.74, p=0.012; median follow-up 14.7 months). The addition of ixazomib to the lenalidomide–dexamethasone regimen was associated with limited additional toxicity and had no adverse impact on patient-reported quality of life. Common grade ≥3 adverse events with ixazomib include gastrointestinal adverse events, rash, and thrombocytopenia. Here, we review the efficacy, safety, pharmacokinetics, and patient-reported quality of life data seen with ixazomib, and discuss the role of this oral agent in the treatment of patients with relapsed/ refractory multiple myeloma, including in patients with high-risk cytogenetic abnormalities and those with multiple prior therapies.",
keywords = "Clinical, Efficacy, Ixazomib, Multiple myeloma, Pharmacokinetics, Proteasome inhibitor, Tolerability",
author = "Richardson, {Paul G.} and Kumar, {Shaji K} and Laubach, {Jacob P.} and Claudia Paba-Prada and Neeraj Gupta and Deborah Berg and {van de Velde}, Helgi and Philippe Moreau",
year = "2017",
month = "8",
day = "22",
doi = "10.2147/JBM.S102328",
language = "English (US)",
volume = "8",
pages = "107--121",
journal = "Journal of Blood Medicine",
issn = "1179-2736",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - New developments in the management of relapsed/refractory multiple myeloma – The role of ixazomib

AU - Richardson, Paul G.

AU - Kumar, Shaji K

AU - Laubach, Jacob P.

AU - Paba-Prada, Claudia

AU - Gupta, Neeraj

AU - Berg, Deborah

AU - van de Velde, Helgi

AU - Moreau, Philippe

PY - 2017/8/22

Y1 - 2017/8/22

N2 - Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlled TOURMALINE-MM1 study, which demonstrated a 35% improvement in progression-free survival with the all-oral combination of ixazomib plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone alone (median: 20.6 vs 14.7 months; hazard ratio: 0.74, p=0.012; median follow-up 14.7 months). The addition of ixazomib to the lenalidomide–dexamethasone regimen was associated with limited additional toxicity and had no adverse impact on patient-reported quality of life. Common grade ≥3 adverse events with ixazomib include gastrointestinal adverse events, rash, and thrombocytopenia. Here, we review the efficacy, safety, pharmacokinetics, and patient-reported quality of life data seen with ixazomib, and discuss the role of this oral agent in the treatment of patients with relapsed/ refractory multiple myeloma, including in patients with high-risk cytogenetic abnormalities and those with multiple prior therapies.

AB - Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlled TOURMALINE-MM1 study, which demonstrated a 35% improvement in progression-free survival with the all-oral combination of ixazomib plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone alone (median: 20.6 vs 14.7 months; hazard ratio: 0.74, p=0.012; median follow-up 14.7 months). The addition of ixazomib to the lenalidomide–dexamethasone regimen was associated with limited additional toxicity and had no adverse impact on patient-reported quality of life. Common grade ≥3 adverse events with ixazomib include gastrointestinal adverse events, rash, and thrombocytopenia. Here, we review the efficacy, safety, pharmacokinetics, and patient-reported quality of life data seen with ixazomib, and discuss the role of this oral agent in the treatment of patients with relapsed/ refractory multiple myeloma, including in patients with high-risk cytogenetic abnormalities and those with multiple prior therapies.

KW - Clinical

KW - Efficacy

KW - Ixazomib

KW - Multiple myeloma

KW - Pharmacokinetics

KW - Proteasome inhibitor

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=85031286640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031286640&partnerID=8YFLogxK

U2 - 10.2147/JBM.S102328

DO - 10.2147/JBM.S102328

M3 - Review article

AN - SCOPUS:85031286640

VL - 8

SP - 107

EP - 121

JO - Journal of Blood Medicine

JF - Journal of Blood Medicine

SN - 1179-2736

ER -